Therapeutic Asset Ratings
534 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
yl-15293
Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.
P1/2
CC
(40)
YL201 for
Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
P1/2
CC
(40)
yl242
Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
P1/2
CC
(40)
Zelenectide Pevedotin
Cancer
BicycleTx Limited
P1/2
CC
(40)
Zggs18 For
Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
P1/2
CC
(40)
zx-101a
Cancer
Nanjing Zenshine Pharmaceuticals
P1/2
CC
(40)
abl501
Cancer
ABL Bio, Inc.
P1
C
(39)
Agen1571
Cancer
Agenus Inc.
P1
C
(39)
apn401
Cancer
invIOs GmbH
P1
C
(39)
Bgb-43395
Cancer
BeOne Medicines
P1
C
(39)
Bgb-C354
Cancer
BeOne Medicines
P1
C
(39)
br101
Cancer
BioRay Pharmaceutical Co., Ltd.
P1
C
(39)
Cln-418
Cancer
Harbour BioMed US, Inc.
P1
C
(39)
Cnsi-Fe
Cancer
Sichuan Enray Pharmaceutical Sciences Company
P1
C
(39)
Efavirenz
Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
P1
C
(39)
es009
Cancer
Elpiscience Biopharma Australia Pty. Ltd.
P1
C
(39)
gamma1 heavy chain humanized (1-453) [VH (Homo sapiens IGHV1-3*01 (80.4%)--(IGHD) -IGHJ3*01 (92.3%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120, CH3 E12, M14, G1v14 CH2 1.3, A1.2 (CH1 R120>K (220) (124-221) hinge 1-15 (222-236), CH2 L1.3>A (240), L1.2>A (241) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453))(124-453)], (226-213')-disulfide with kappa light chain humanized (1'-213') [V-KAPPA (Homo sapiens IGKV3-11*01 (82.1%) -IGKJ2*02 (100%), CDR-IMGT [5.3.9] (27-31.49-51.88-96)) (1'-106') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (152), V101 (190) (107'-213')], dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, glycoform alfa
Cancer
Elpiscience Biopharma, Ltd.
P1
C
(39)
gc101
Advanced Solid Tumor
Shanghai Juncell Therapeutics
P1
C
(39)
hbm1020
Cancer
Harbour BioMed US, Inc.
P1
C
(39)
hr19024
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
P1
C
(39)
Hrs-1167
Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1
C
(39)
Ibi 360
Cancer
Innovent Biologics (Suzhou) Co. Ltd.
P1
C
(39)
Immunoglobulin G1, anti-(human/Macaca mulatta tumor necrosis factor receptor superfamily 4) (human-Mus musculus monoclonal YH002 ?1-chain), disulfide with human-Mus musculus monoclonal YH002 ?-chain, dimer
Advanced Solid Tumor
Eucure (Beijing) Biopharma Co., Ltd
P1
C
(39)
io-108
Cancer
Immune-Onc Therapeutics
P1
C
(39)
msp008-22
Cancer
Godavari Biorefineries Limited
P1
C
(39)
Showing 226 to 250 of 534 assets
Previous
Page 10 of 22
Next
